Welcome to the AstraZeneca | Daiichi-Sankyo Sponsored Lunch Symposium

The Changing Paradigm for Treating HER2+ eBC.

You’re invited to an engaging and practical symposium exploring the evolving management of high-risk HER2-positive early breast cancer (eBC). As treatment options continue to expand across the neoadjuvant and adjuvant settings, clinicians are increasingly faced with complex decisions about tailoring therapy to achieve the best outcomes for patients.

Join internationally recognised experts Professor Nadia Harbeck, Dr Antonia Pearson, Professor Bruce Mann and Associate Professor Gillian Lamoury as they present:

  • An overview of the HER2+ eBC landscape. 
  • Real-world case studies exploring both the high-risk neoadjuvant setting and the high-risk adjuvant setting.
  • Interactive panel discussions following each case study, giving you the opportunity to hear different clinical perspectives and ask questions of our expert faculty.

Don’t miss this opportunity to gain valuable insights from leading specialists, explore practical approaches to managing HER2-positive early breast cancer, and connect with colleagues from across the oncology community. We look forward to seeing you there!

Meet our Guest Speakers

We are pleased to introduce the following speakers at the AstraZeneca | Daiichi-Sankyo sponsored Lunch Symposium. 

Nadia Harbeck

International Guest Speaker

Bruce Mann

Conference Guest Speaker

Gillian Lamoury

Conference Guest Speaker

Antonia Pearson

Symposium Guest Speaker